A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. View (VRTX) real-time stock price, chart, news, analysis, analyst reviews and more.

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue of $2.77 billion, up 3% year over year. In addition, Vertex revealed ...

Vertex Pharmaceuticals Incorporated VRTX will release its fourth-quarter financial results, after the closing bell, on Monday, Feb. 10, 2025. Analysts expect the Boston, Massachusetts-based ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.06% to $460.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.28 ...

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment. It’s the first new class of pain treatment approved in more than 20 years, Vertex says.

Shares of Vertex Pharmaceuticals (VRTX-1.65%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening ...

Vertex Pharmaceuticals (NASDAQ: VRTX) ... Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip. Alex Carchidi, The Motley Fool. December 26, 2024 at 8:30 AM.